Report
Thomas J. Schiessle
EUR 190.00 For Business Accounts Only

Gerresheimer 2020e: Mehr Wachstum - weniger Profit und Einmaleffekte

 

Der neue Vorstand hatte 2019 Wachstumsinitiativen gestartet und will und muss 2020 „liefern“; er gibt sich optimistisch und schlägt eine Dividende von € 1,20 (Vj. € 1,15/Aktie) vor. Im Q1/20 noch verhalten, soll das Wachstum im weiteren Jahresverlauf deutlich - auf ca. 4-5 % - zunehmen.

Unsere Schätzungen sind leicht anzupassen und verstehen sich, wie die am 19.02.20 erstmals veröffentlichte Guidance 2020, als FX-neutrale Planung.

Underlying
Gerresheimer AG

Gerresheimer is a holding company. Through its subsidiaries, Co. manufactures glass and plastic products for the pharma and healthcare industry. Co.'s operates in three divisions: Plastics & Devices, which its product portfolio includes products for the administration of medicines, such as insulin pens, inhalers, and prefillable syringes; Primary Packaging Glass, which produces glass primary packaging for medicines and cosmetics, such as pharma jars, ampoules, injection vials, cartridges, perfume flacons, and cream jars; and Life Science Research, which produces laboratory glassware for research, development, and analytics, such as beakers, Erlenmeyer flasks, and measuring cylinders.

Provider
EQUITS GmbH
EQUITS GmbH

EQUI.TS GmbH is an innovative, equity research boutique based in Frankfurt (Germany). It is operated by its original founders and has established a reputation as a quality research provider over a period of more than 10 years. Although it generally does not focus on any particular branch of industry, its analyses often revolve around technology and growth stocks.

Analysts
Thomas J. Schiessle

Other Reports on these Companies
Other Reports from EQUITS GmbH
Other Reports from these Analysts

ResearchPool Subscriptions

Get the most out of your insights

Get in touch